Quantitative p53 immunostaining aids in the detection of prevalent dysplasia.

Autor:	Neyaz A; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Rickelt S; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Yilmaz OH; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Parrack PH; Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lu C; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Yilmaz O; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Wu EY; Pathology, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA., Choi WT; Pathology, University of California, San Francisco, California, USA., Gala M; Department of Medicine, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, USA., Ting DT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Odze RD; Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Patil DT; Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Deshpande V; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA vikramdirdeshpande@gmail.com.
Jazyk:	angličtina
Zdroj:	Journal of clinical pathology [J Clin Pathol] 2023 Sep; Vol. 76 (9), pp. 582-590. Date of Electronic Publication: 2023 Feb 23.
DOI:	10.1136/jcp-2022-208721
Abstrakt:	Aims: The lack of accepted scoring criteria has precluded the use of p53 in routine practice. We evaluate the utility of automated quantitative p53 analysis in risk stratifying Barrett's oesophagus (BE) patients using non-dysplastic BE (NDBE) biopsies in a multicentric cohort of BE progressor (P) and non-progressor (NP) patients. Methods: NDBE biopsies prior to the diagnosis of advanced neoplasia from 75 BE-P, and index and last surveillance biopsies from 148 BE-NP were stained for p53, and scored digitally as 1+, 2+ and 3+. A secondary cohort of 30 BE-P was evaluated. Results: Compared with BE-NP, BE-P was predominantly men (p=0.001), ≥55 years of age (p=0.008), with longer BE segments (71% vs 33%; p<0.001). The mean number of 3+p53 positive cells and 3+ positive glands were significantly more in BE-P versus BE-NP NDBE biopsies (175 vs 9.7, p<0.001; 9.8 vs 0.1; p<0.001, respectively). At a cut-off of ≥10 p53 (3+) positive cells, the sensitivity and specificity of the assay to identify BE-P were 39% and 93%. On multivariate analysis, scoring p53 in NDBE biopsies, age, gender and length of BE were significantly associated with neoplastic progression. 54% of patients classified as prevalent dysplasia showed an abnormal p53 immunohistochemical stain. These findings were validated in the secondary cohort. Conclusions: Automated p53 analysis in NDBE biopsies serves as a promising tool for assessing BE neoplastic progression and risk stratification. Our study highlights the practical applicability of p53 assay to routine surveillance practice and its ability to detect prevalent dysplasia. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu